Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time.
Clin Case Rep
; 5(1): 75-76, 2017 Jan.
Article
em En
| MEDLINE
| ID: mdl-28096995
ABSTRACT
Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first-in-class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long-term ibrutinib promotes a high response rate that improves in quality with time.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article